Approvals of high-risk devices drop as de novos take off
Changes at the FDA have altered the device approval landscape, with the de novo route now the most popular.
Roche dominates 2019’s big patent expiries
Of the five biggest products set to lose exclusivity in the US this year the Swiss pharma giant owns three: Avastin, Herceptin and Tarceva.
As the US shutdown rolls on, blockbuster launches line up for 2019
A look at the biggest potential drug launches this year reveals a long list of blockbusters from the likes of Alexion and Abbvie. But what impact will the shutdown have?
Keytruda wins 2018’s biggest sales upgrade
Vantage takes a look at the sellside’s naughty and nice list for 2018: prospects improved considerably for Merck & Co’s Keytruda and Abbvie’s Mavyret, the latter…
Lilly gets fresher but Roche’s rot continues
Lilly reduces its reliance on older products, but Roche and Sanofi still need fresh blood.
Biotech's big-bucks buybacks begin to burn
If big biotech cannot deliver innovation investors might start demanding shareholder payout plans that look more like big pharma's.
The most disputed sales outlooks in biopharma
Celgene’s Revlimid ranks as biopharma’s most contested blockbuster, with a huge spread in future sales forecasts, while drugs from Bristol-Myers Squibb and Sanofi also…
Roche leaves Abbott in the dust when it comes to US approval times
The Swiss group has succeeded with its internally developed diagnostics, but buying in innovation has served Becton Dickinson well.
Are all new sales created equal?
Pipeline projects are forecast to contribute a substantial proportion of future sales at Abbvie and Lilly, though the same cannot be said for all big drug developers.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.